AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Comparative Self-collection for Cervical Cancer Screening Pivotal Study

RecruitingNAAges 25 Years - 65 YearsFemaleMel Mont Medical
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

To evaluate whether individuals drawn from the intended use population can successfully interpret and follow the IFU for the Mia by XytoTest self-collection device and perform a vaginal sample collection yielding sufficient cellular material for primary hrHPV screening. To assess the clinical performance of Mia self-collected vaginal specimens by evaluating agreement with paired clinician-collected cervical specimens for the detection of high-risk HPV, when both specimen types are analyzed using the cobas HPV Test (Roche Molecular Systems). Residual samples may be used to determine adequacy for additional assays that require vaginal and/or cervical specimens (such as mRNA E6 and E7 Biomarker Test, dual stain cytology).

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: Group 1: General Population Group 1. Participants are 25 to 65 years of age and willing to provide informed consent. 2. Participants have an intact cervix. Group 2: Enriched Population Group 1. Participants are 25 to 65 years of age and willing to provide informed consent. 2. Participants have an intact cervix. 3. One or more of: prior diagnosis of hrHPV within previous 6 months; abnormal cervical Pap cytology result of HSIL or higher (HSIL, AIS, or invasive carcinoma per the Bethesda 2014 system) within previous 6 months; and/or presenting for colposcopy/LEEP/excisional intervention. Exclusion Criteria: Apply to all groups: 1. Impaired decision-making capacity or inability to provide informed consent. 2. History of partial or total hysterectomy, including removal of the cervix. 3. Cervical tissue alteration or surgery within 5 months prior (conization, LEEP, laser ablation, or cryotherapy). 4. Current pregnancy (based on self-reporting). 5. Active menstruation at time of specimen collection. 6. Vaginal bleeding within 48 hours. 7. Have had sex or used tampons, creams, or other vaginal products in the last 48 hours. 8. Participation in another clinical study that, in the investigator's opinion, would interfere with the results of this study. 9. Any medical reason that, in the investigator's opinion, would disqualify the participant for a routine pelvic exam with cervical sample collection.
๐Ÿ’Š

What it tests

  • Mia by XytoTest
  • Rovers Cervex-Brush
๐Ÿ“

Where

11 sites
ASR Arizona CGA
Phoenix, United States
Integrated Clinical Research
Sherman Oaks, United States
Altus Clinical Research
Lake Worth, United States
Zenacare Research
North Miami Beach, United States
ASR Idaho CGI
Boise, United States
Boeson Research - Great Falls
Great Falls, United States
Unified Women's Clinical Research
Raleigh, United States
Innovo-Wilmington Health
Wilmington, United States

โ€ฆand 3 more on ClinicalTrials.gov.

๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy